Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry st...
Main Authors: | Lawrence Mbuagbaw, Lorenzo Guglielmetti, Catherine Hewison, Nyasha Bakare, Mathieu Bastard, Eric Caumes, Mathilde Fréchet-Jachym, Jérôme Robert, Nicolas Veziris, Naira Khachatryan, Tinatin Kotrikadze, Armen Hayrapetyan, Zaza Avaliani, Holger J. Schünemann, Christian Lienhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2019-05-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/25/5/18-1823_article |
Similar Items
-
Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01) -
A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
by: Tae Sun Shim, et al.
Published: (2023-01-01) -
Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01) -
Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01) -
Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis
by: Prakasini Satapathy, et al.
Published: (2024-03-01)